Expert consensus on hypofractionated radiotherapy for breast cancer (2025 edition)
10.3760/cma.j.cn113030-20250213-00060
- VernacularTitle:乳腺癌大分割放射治疗专家共识（2025版）
- Author:
Yufei LU
1
;
Hong GE
;
Ting WANG
;
Hao WANG
;
Chengliang YANG
;
Ye-xiong LI
;
Hao JING
;
Lu CAO
;
Chi ZHANG
Author Information
1. 郑州大学附属肿瘤医院/河南省肿瘤医院/中国医学科学院肿瘤医院河南医院放疗科，郑州 450000
- Publication Type:Journal Article
- Keywords:
Breast neoplasms;
Radiotherapy;
Moderately hypofractionated;
Ultrahypofractionated;
Local control rate;
Adverse effects
- From:
Chinese Journal of Radiation Oncology
2025;34(12):1171-1182
- CountryChina
- Language:Chinese
-
Abstract:
Breast cancer is one of the most common malignant tumors, and postoperative radiotherapy remains an essential component of its treatment. In recent years, hypofractionated radiotherapy has gradually become the recommended approach for postoperative breast cancer treatment. Compared with conventional fractionated radiotherapy, hypofractionated regimens shorten the overall treatment duration, enhance patient convenience, and reduce treatment costs, while achieving comparable long-term efficacy and maintaining good quality of life. Based on relevant domestic and international studies and clinical experience, this consensus establishes expert recommendations regarding indications, prescribed doses, dose constraints for organs at risk (OAR), implementation methods, and plan evaluation for hypofractionated radiotherapy after breast cancer surgery, with a particular focus on moderately hypofractionated (MHF) and ultrahypofractionated (UHF) regimens. MHF radiotherapy is applicable to whole-breast irradiation, chest wall irradiation, and regional nodal irradiation, and is suitable for most breast cancer patients. UHF radiotherapy, which employs a higher dose per fraction to further shorten the treatment course, is suitable for patients requiring rapid therapy or prioritizing treatment convenience. Although the short-term efficacy of UHF radiotherapyis similar to that of MHF radiotherapy, its long-term efficacy and safety require further clinical validation. Meanwhile, potential adverse effects of UHF, such as breast induration and atrophy, should be carefully assessed. Therefore, radiotherapy dose and fractionation regimen should be individualized according to patient-specific factors, particularly considering OAR dose constraints. Rational selection of radiotherapy regimens can minimize adverse effects while maintaining therapeutic efficacy, ultimately improving patient outcomes and quality of life. This consensus provides scientific guidance for the clinical and research application of hypofractionated radiotherapy in breast cancer.
